Pharmaceutical Launch Sequencing

$4,895.00 $3,495.00

Setting a global launch sequence for pharmaceutical products requires extensive research, planning and coordination.  Use this report to establish and improve cross-functional coordination, a crucial aspect to managing launch sequences, and work with regulatory teams to manage the licensing cascade.  Set clear roles for final responsibility for approving launch sequences, and understand the latest trends in launches across all market types and launch waves.

Download Now! speak-to-an-expert

Report Details and Features

From country to county, drug launches happen in a certain order. How do companies develop their pharmaceutical launch sequencing plans? Which markets come first? As much as possible, companies want to prioritize markets where they get the most favorable pricing.

Report details:

  • 3 chapters + an Executive Summary
  • 79 pages
  • 400+ metrics
  • 65+ graphics

Data have been split by team region:

  • United States
  • Europe
  • Emerging Markets

Data have also been split by company size:

  • Top 10
  • Top 50
  • Small

Data highlights include: 

  • Timelines for beginning pharmaceutical launch sequencing planning
    • Current and ideal start times for launch sequencing
  • Organization of launch sequencing responsibilities
  • Metrics for which functions are responsible for approving launch sequencing plans
  • Number of FTEs on dedicated pharmaceutical launch sequencing committees
  • Launch sequencing committee membership
  • Funding dedicated pharmaceutical launch sequencing committees
  • Spending levels for launch sequencing activities
  • Metrics on pharmaceutical launch sequencing development tools
    • Spending levels
    • Approach and use of tools
  • Individual launch sequence budget levels
  • Timeline for developing launch sequence
  • Number of meetings with regulatory groups
  • Frequency of sequence reassessments
  • Prototypical launch sequence
  • Launch wave metrics
    • Division of countries per launch wave
    • Year-over-year trends in first- and second-wave launches

Top Reasons to Buy This Pharmaceutical Launch Sequencing Report

Establish and improve cross-functional coordination: Cross-functional coordination is crucial to managing launch sequences. It is especially important when working with regulatory teams to manage the licensing cascade. This study includes detailed best practices and strategies for how companies should work across functions within the organization to coordinate launch sequencing and provide important regulatory and market guidance to shape the product launch. It also includes global launch sequencing budgets and which US or global groups contribute the highest spend.

Involve C-suite executives in final launch sequence approvals: Because launch sequencing has such a large impact on a brand’s potential revenue, C-level executives are best positioned to review and approve plans. This benchmarking study provides detailed data on the composition of committees that determine pharmaceutical launch sequences. It also provides discussion on the advantages and disadvantages of employing dedicated launch sequencing committees.

Shift emerging markets to second wave launches: Large and comparatively wealthy US and European markets are typically high priorities for first launch waves. However, heavily populated emerging markets, such as the BRIC nations, are more commonly following in second wave launches. This report includes data analysis to support moving emerging market launches earlier in the launch sequence. Data include launch sequencing comparisons between 2012 and 2015 earlier in the launch sequence. Data include launch sequencing comparisons between 2012 and 2015.

You may also be interested in our Market Access library

Excerpt from Pharmaceutical Launch Sequencing

At many pharmaceutical firms, C-level executives have ultimate responsibility for launch sequence decisions. Because launch sequencing has such a large impact on a brand’s potential revenue, these high-level executives — or in some publicly traded companies, a chairman and executive board — are best positioned to review and approve plans. “How they sequence their launch, or when they invest, is [a company’s] core expense,” explained a consulting Company C executive.

The majority of surveyed firms, 62%, grant launch sequencing approval to C-level executives or the company’s executive board. Another 13% of surveyed companies each look to marketing teams or to specialized launch sequencing committees for final approval. Only 6% each look to market access teams or brand managers.

Sample List of Companies that Participated in this Study:

Pharmaceutical launch sequencing participants

Table of Contents

6             Executive Summary: Maximizing Revenue and Achieving Global Market Access

16           Supporting Global Launch Sequencing Through Structure and Spending

17           Developing Launch Sequencing Efforts to Support Emerging Brands

26           Organizing Launch Sequencing Responsibilities Through Internal Structure

37           Resourcing Launch Sequencing Processes and Tools

44           Coordinating Successful Launch Sequences

48           Managing Launch Sequencing Tools

56           Developing and Maintaining Launch Sequences

65           Trends and Practices for Global Launch Sequencing

67           Global Trends in Launch Sequencing

73           Identifying Key Aspects of Individual Market Launches

CHARTS AND GRAPHICS

6             Maximizing Revenue and Achieving Global Market Access

8             Figure E.1: Business Unit with Ultimate Responsibility for Approving Launch Sequence: All Companies

9             Figure E.2: Tools Used in Launch Sequence Development: All Companies

10           Figure E.3: Year-Over-Year Trends in Second Wave Launches: All Companies

11            Figure E.4: Number of Meetings per Month with Regulatory Group About Launch Sequences, by Group Region

16           Supporting Global Launch Sequencing Through Structure and Spending

17           Developing Launch Sequencing Efforts to Support Emerging Brands

18           Figure 1.1: Average Number of Months Before Launch Companies Begin Launch Sequencing, by Group Type

19           Figure 1.2: Current and Ideal Start Times for Launch Sequencing: Top 10 and Top 50 Companies

20           Figure 1.3: Current and Ideal Start Time for Launch Sequencing: Small Companies

22           Figure 1.4: Business Unit with Ultimate Responsibility for Approving Launch Sequence: All Companies

23           Figure 1.5: Business Unit with Ultimate Responsibility for Approving Launch Sequence, by Company Size

24           Figure 1.6: Business Unit with Ultimate Responsibility for Approving Launch Sequence: Global Groups

24           Figure 1.7: Business Unit with Ultimate Responsibility for Approving Launch Sequence: US Groups

25           Figure 1.8: Business Unit with Ultimate Responsibility for Approving Launch Sequence: EU Groups

25           Figure 1.9: Business Unit with Ultimate Responsibility for Approving Launch Sequence: Emerging Markets Groups

26           Organizing Launch Sequencing Responsibilities Through Internal Structure

27           Figure 1.10: Organization of Launch Sequencing Responsibilities: All Companies

28           Figure 1.11: Organization of Launch Sequencing Responsibilities, by Company Type

29           Figure 1.12: Organization of Launch Sequencing Responsibilities, by Group Region

30           Figure 1.13: Average Number of FTEs on Launch Sequencing Committees, by Committee Type

32           Figure 1.14: Members of Ad Hoc Launch Sequencing Committees: Top 10 and Top 50 Companies

32           Figure 1.15: Members of Ad Hoc Launch Sequencing Committees: Small Companies

33           Figure 1.16: Groups Involved in Ad Hoc Launch Sequencing Committees: All Companies

34           Figure 1.17: Groups Involved in Ad Hoc Launch Sequencing Committees: Top 10 and Top 50 Companies

34           Figure 1.18: Groups Involved in Ad Hoc Launch Sequencing Committees: Small Companies

35           Figure 1.19: Number of FTEs on Dedicated Launch Sequencing Committees: All Companies

36           Figure 1.20: Funding of Dedicated Launch Sequencing Committees: All Companies

37           Resourcing Launch Sequencing Processes and Tools

38           Figure 1.21: Spending in 2015 on Global Launch Sequencing Activities: All Companies

40           Figure 1.22: Tools Used in Launch Sequence Development: All Companies

40           Figure 1.23 Tools Used in Launch Sequence Development: Top 10 and Top 50 Companies

41           Figure 1.24: Tools Used in Launch Sequence Development: Small Companies

42           Figure 1.25: Tools Used in Launch Sequence Development: US Groups

42           Figure 1.26: Tools Used in Launch Sequence Development: EU Groups

44           Coordinating Successful Launch Sequences

45           Figure 2.1: Approach to Building Launch Sequence: All Companies

46           Figure 2.2: Approach to Launch Sequence, by Company Type

47           Figure 2.3: Approach to Launch Sequence, by Group Region

48           Managing Launch Sequencing Tools

49           Figure 2.4: Spending on Launch Sequencing Tools: All Companies

49           Figure 2.5: Spending on Launch Sequencing Tools, by Company Type

51           Figure 2.6: Spending on Launch Sequencing Tools: Pricing Studies, by Company

51           Figure 2.7: Spending on Launch Sequencing Tools: Regulatory Guidance, by Company

52           Figure 2.8: Spending on Launch Sequencing Tools: Payer Advisory Boards, by Company

52           Figure 2.9: Spending on Launch Sequencing Tools: Market Research, by Company

53           Figure 2.10: Total Spending on a Single Launch Sequence, by Company

54           Figure 2.11: Allocation of Spending on a Single Launch Sequence: All Companies

55           Figure 2.12: Allocation of Spending on a Single Launch Sequence: Top 10 and Top 50 Companies

55           Figure 2.13: Allocation of Spending on a Single Launch Sequence: Small Companies

56           Developing and Maintaining Launch Sequences

57           Figure 2.14: Number of Working Hours to Develop Custom Launch Sequences: Top 10 and Top 50 Companies

57           Figure 2.15: Number of Working Hours to Develop Custom Launch Sequences: Small Companies

58           Figure 2.16: Number of Working Hours to Develop Custom Launch Sequences, by Portfolio Size

59           Figure 2.17: Frequency of Launch Sequencing Group Communication with Regulatory Teams: All Companies

60           Figure 2.18: Number of Meetings per Month with Regulatory Group About Launch Sequences: All Companies

61           Figure 2.19: Number of Meetings per Month with Regulatory Group About Launch Sequences, by Company Type

61           Figure 2.20: Number of Meetings per Month with Regulatory Group About Launch Sequences, by Group Region

63           Figure 2.21: Frequency of Launch Sequence Reassessments: All Companies

63           Figure 2.22: Frequency of Launch Sequence Reassessments, by Company Type

64           Figure 2.23: Frequency of Launch Sequence Reassessments, by Group Region

65           Trends and Practices for Global Launch Sequencing

67           Figure 3.1: Prototypical Launch Sequence for Pharmaceutical Products

67           Global Trends in Launch Sequencing

68           Figure 3.2: Cumulative Percentage of Companies Launching Products in US and Major Five EU Markets,* by Launch Wave

69           Figure 3.3: Division of Countries by Launch Wave: US and Major Developed Markets

70           Figure 3.4: Division of Countries by Launch Wave: Asian Markets

70           Figure 3.5: Division of Countries by Launch Wave: Latin American Markets

71           Figure 3.6: Year-Over-Year Trends in First Wave Launches: All Companies

72           Figure 3.7: Year-Over-Year Trends in Second Wave Launches: All Companies

73           Identifying Key Aspects of Individual Market Launches

74           Figure 3.8: Percentage of Companies per Launch Wave: US Launches

75           Figure 3.9: Percentage of Companies per Launch Wave: UK Launches

76           Figure 3.10: Percentage of Companies per Launch Wave: Germany Launches

77           Figure 3.11: Percentage of Companies per Launch Wave: France Launches

79           Figure 3.12: Percentage of Companies per Launch Wave: Spain Launches

79           Figure 3.13: Percentage of Companies per Launch Wave: Italy Launches